5 Heurteaux et al., Nature Neuroscience (2006)TREK-1 knockout produces a depression-resistant phenotype, establishing TREK-1 as an antidepressant target
Who It Is For Adults over 40 who are proactively focused on healthspan and longevity Patients who want to address aging at the cellular level rather than just managing symptoms Individuals interested in measurable anti-aging results (paired with TrueAge epigenetic testing to track biological age) Patients who have optimized the basics (sleep, nutrition, exercise) and want to add the next level of cellular support Those experiencing multiple signs of accelerated aging fatigue, cognitive decline, slow recovery, metabolic dysfunction simultaneously What to Expect Weeks 1-4: Improved sleep quality and energy (from sermorelin and NAD+)
Front Pharmacol (2021) 11
UK Research Cluster Hubs BPC-157 UK Research Guide TB-500 UK Research Guide GLP-1 Peptides Complete Research Reference Retatrutide UK Research Guide Tirzepatide UK Research Guide Research-Grade Peptides Standards Guide UK Research Peptide Buying Guide Disclaimer: BPC-157 is an investigational peptide not approved for human use in the UK, EU or US
- Mood and Libido Enhancement: Some users report improved mood and libido
Bock-Marquette I, et al
